Ulka Vaishampayan

26PUBLICATIONS
189CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jan 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.

Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente

|Sep 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).

Irene Tsung, David C Smith, Elisabeth I Heath

|Aug 04, 2025
Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial.

Emiliano Calvo, Valentina Boni, Olivier Dumas

|Jul 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Robert Wesolowski, Hope S Rugo, Jennifer M Specht

|Jun 06, 2025
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma.

Steven M Monda, Srinivas Nallandhighal, Ulka Vaishampayan

|Feb 18, 2025
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.

Sumanta K Pal, Yohann Loriot, Andrea Necchi

Pageof 5

Frequent Collaborators

8 joint publications

Sumanta Kumar Pal

5 joint publications

Elisabeth I Heath

4 joint publications

Rana R McKay

3 joint publications

Charles B Nguyen